Effects of Transcranial Direct Current Stimulation (tDCS) in the Management of Suicidal Ideation (tDCS-IDSDEP)

• ClinicalTrials.gov Identifier: NCT06009523
• Recruitment Status: Recruiting
• First Posted: August 24, 2023
• Last Update Posted: February 8, 2024
• Sponsor: Centre Hospitalier Henri Laborit
• Information provided by (Responsible Party): Centre Hospitalier Henri Laborit

Study Description

Brief Summary:

The main objective of this study is to demonstrate that 15 transcranial direct current stimulation (tDCS) sessions of 30 minutes at 2 mA intensity are effective to reduce suicidal ideation

Condition or disease	Intervention/treatment	Phase
Depression and Suicide	Device: Transcranial direct current stimulation	Not Applicable

Detailed Description:

After being informed about the study and potential risks, all patients giving written informed consent will undergo a screening visit to determine eligibility for study entry. Patient who meet the eligibility requirements be able to start the 15 tDCS sessions at the rate of one session per day. After the last session, patients will perform three follow-up visits on D19, D49 and D79

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 50 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Effects of Transcranial Direct Current Stimulation (tDCS) in the Management of Suicidal Ideation in Treatment-resistant Depression : a Pilot Study
• Actual Study Start Date: October 26, 2023
• Estimated Primary Completion Date: September 1, 2026
• Estimated Study Completion Date: December 1, 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Active tDCS; Participants received an active tdcs: transcranial direct current with an intensity of 2 mA for 30 minutes	Device: Transcranial direct current stimulation; 1 stimulation per day during 15 days.

Outcome Measures

Primary Outcome Measures :

1. Change from Baseline in suicidal ideation on the Scale for Suicide Ideation (SSI) at "Day 19" [ Time Frame: Baseline and "Day 19" ]
   The main judgment criterion is the evolution of suicidal ideation which is evaluated by the Beck Scale for Suicide Ideation (SSI) between Baseline and "Day 19"

Secondary Outcome Measures :

1. Change from Baseline of clinical response defined by the MADRS (Montgomery and Asberg depression scale) at "Day 19" post-tDCS sessions [ Time Frame: Baseline and "Day 19" ]
   The Montgomery-Åsberg Depression Rating Scale (MADRS) was developed to provide an assay of depressive symptom severity for use in the investigation of treatment response to antidepressant medication. The MADRS takes 20-60 minutes to be completed by interview. MADRS-S has 9 items , and each item is scored between 0 (minimum) and 6 (maximum). The scores for all 9 items were added, and cutoff scores for the MADRS-S were defined for level of depression (depression: 0-12 = minimal, 13-19 = mild, 20-34 = moderate, ≥ 35 = severe).
2. Change from Baseline of clinical response defined by the MADRS (Montgomery and Asberg depression scale) at "Day 49" post-tDCS sessions [ Time Frame: Baseline and "Day 49" ]
   The Montgomery-Åsberg Depression Rating Scale (MADRS) was developed to provide an assay of depressive symptom severity for use in the investigation of treatment response to antidepressant medication. The MADRS takes 20-60 minutes to be completed by interview. MADRS-S has 9 items , and each item is scored between 0 (minimum) and 6 (maximum). The scores for all 9 items were added, and cutoff scores for the MADRS-S were defined for level of depression (depression: 0-12 = minimal, 13-19 = mild, 20-34 = moderate, ≥ 35 = severe).
3. Change from Baseline of clinical response defined by the MADRS (Montgomery and Asberg depression scale) at "Day 79" post-tDCS sessions [ Time Frame: Baseline and "Day 79" ]
   The Montgomery-Åsberg Depression Rating Scale (MADRS) was developed to provide an assay of depressive symptom severity for use in the investigation of treatment response to antidepressant medication. The MADRS takes 20-60 minutes to be completed by interview. MADRS-S has 9 items , and each item is scored between 0 (minimum) and 6 (maximum). The scores for all 9 items were added, and cutoff scores for the MADRS-S were defined for level of depression (depression: 0-12 = minimal, 13-19 = mild, 20-34 = moderate, ≥ 35 = severe).
4. Change from Baseline in suicidal ideation assessed by the implicit association test at "Day 19" post-tDCS sessions [ Time Frame: Baseline and "Day 19" ]
   The Implicit Association Test (IAT) is a computer-based test measuring implicit mental associations between two concepts. The IAT uses reaction times to categorize stimuli that appear in the middle of the screen into two target categories, in our study: "Death" (suicide, dies, funeral, lifeless, deceased) and "Life". (survive, grow, breathe, alive, live) and/or in two attribute categories "Me" (me, myself, my, mine, I) and "Not Me" (them, they, their, his, others) . and subjects rapidly classify them by pressing one of two keys (the category of right (by pressing the I key) or left (by pressing the E key). According to the logic of the IAT, "D positive" scores represent a strong implicit association between "Me" and "Death". We will use Greenwald's improved algorithm to analyze responses.
5. Change from Baseline in suicidal ideation assessed by the implicit association test at "Day 49" post-tDCS sessions [ Time Frame: Baseline and "Day 49" ]
   The Implicit Association Test (IAT) is a computer-based test measuring implicit mental associations between two concepts. The IAT uses reaction times to categorize stimuli that appear in the middle of the screen into two target categories, in our study: "Death" (suicide, dies, funeral, lifeless, deceased) and "Life". (survive, grow, breathe, alive, live) and/or in two attribute categories "Me" (me, myself, my, mine, I) and "Not Me" (them, they, their, his, others) . and subjects rapidly classify them by pressing one of two keys (the category of right (by pressing the I key) or left (by pressing the E key). According to the logic of the IAT, "D positive" scores represent a strong implicit association between "Me" and "Death". We will use Greenwald's improved algorithm to analyze responses.
6. Change from Baseline in suicidal ideation assessed by the implicit association test at "Day 79" post-tDCS sessions [ Time Frame: Baseline and "Day 79" ]
   The Implicit Association Test (IAT) is a computer-based test measuring implicit mental associations between two concepts. The IAT uses reaction times to categorize stimuli that appear in the middle of the screen into two target categories, in our study: "Death" (suicide, dies, funeral, lifeless, deceased) and "Life". (survive, grow, breathe, alive, live) and/or in two attribute categories "Me" (me, myself, my, mine, I) and "Not Me" (them, they, their, his, others) . and subjects rapidly classify them by pressing one of two keys (the category of right (by pressing the I key) or left (by pressing the E key). According to the logic of the IAT, "D positive" scores represent a strong implicit association between "Me" and "Death". We will use Greenwald's improved algorithm to analyze responses.
7. Change from Baseline in quality-of-life assessed by the SF36 (Short Form (36) Health Survey) at "Day 19" post-tDCS sessions [ Time Frame: Baseline and "Day 19" ]
   The Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) is an indicator of overall health status. The SF-36 is validated and has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100, so that the lowest and highest possible scores are 0 and 100, respectively. Lower scores = more disability, higher scores = less disability. Sections : vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health.
8. Change from Baseline in quality-of-life assessed by the SF36 (Short Form (36) Health Survey) at "Day 49" post-tDCS sessions [ Time Frame: Baseline and "Day 49" ]
   The Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) is an indicator of overall health status. The SF-36 is validated and has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100, so that the lowest and highest possible scores are 0 and 100, respectively. Lower scores = more disability, higher scores = less disability. Sections : vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health.
9. Change from Baseline in quality-of-life assessed by the SF36 (Short Form (36) Health Survey) at "Day 79" post-tDCS sessions [ Time Frame: Baseline and "Day 79" ]
   The Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) is an indicator of overall health status. The SF-36 is validated and has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100, so that the lowest and highest possible scores are 0 and 100, respectively. Lower scores = more disability, higher scores = less disability. Sections : vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age over 18 years
• Written informed consent
• Diagnosis of recurrent or isolated depressive episode according to DSM IV criteria (A.P.A. 1994).
• Stable antidepressant treatment for 3 weeks
• MADRS score ≥ 20
• SSI score > 3
• Subject affiliated to a health insurance system
• Woman with effective contraception and agreeing to maintain it throughout the study period.

Exclusion Criteria:

• Depression with psychotic features Axis I (DSM IV) co-morbid diagnosis of schizophrenia, alcohol and/or other substance dependence (or abuse) (lifetime)
• Patient who has already undergone an electroconvulsive therapy course for the current episode and does not respond to this treatment
• Patient deprived of liberty
• Patient with high suicide risk (item 10 MADRS > 4) in the absence of hospitalization
• Contraindication to tDCS: intracerebral metallic implant (with the exception of dental implants), cardiac pacemaker, active or non-implanted devices in the region of the head, acute eczema in the planned stimulation area
• Pregnant, parturient or breastfeeding woman
• Simultaneous participation in another interventional research

Contacts and Locations

Contacts

Contact: Ghina Harika-Germaneau; 05.16.52.61.18; ghina.harika-germaneau@ch-poitiers.fr

Locations

France

Centre Hospitalier Nord-Deux-Sèvres; Recruiting

Faye-l'abbesse, France

Contact: Issa Wassouf wassouf.issa@chnds.fr

Centre Hospitalier Henri Laborit; Recruiting

Poitiers, France

Contact: Ghina Harika-Germaneau ghina.harika-germaneau@ch-poitiers.fr

Sponsors and Collaborators

Centre Hospitalier Henri Laborit

More Information

• Responsible Party: Centre Hospitalier Henri Laborit
• ClinicalTrials.gov Identifier: NCT06009523
• Other Study ID Numbers: 2022-A01454-39
• First Posted: August 24, 2023
• Last Update Posted: February 8, 2024
• Last Verified: February 2024

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Centre Hospitalier Henri Laborit:

tDCS

Additional relevant MeSH terms:

Depression; Suicide; Suicidal Ideation; Behavioral Symptoms; Self-Injurious Behavior